Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

Public microbial resources centres: key hubs for FAIR microorganisms and genetic materials.

Becker P, Bosschaerts M, Chaerle P, Daniel HM, Hellemans A, Olbrechts A, Rigouts L, Wilmotte A, Hendrickx M.

Appl Environ Microbiol. 2019 Aug 30. pii: AEM.01444-19. doi: 10.1128/AEM.01444-19. [Epub ahead of print] Review.

PMID:
31471301
2.

Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistance.

Torrea G, Ng KCS, Van Deun A, André E, Kaisergruber J, Ssengooba W, Desmaretz C, Gabriels S, Driesen M, Diels M, Asnong S, Fissette K, Gumusboga M, Rigouts L, Affolabi D, Joloba M, De Jong BC.

Sci Rep. 2019 Aug 14;9(1):11826. doi: 10.1038/s41598-019-48401-z.

3.

How well do routine molecular diagnostics detect rifampicin heteroresistance in Mycobacterium tuberculosis?

Ng KCS, Supply P, Cobelens FGJ, Gaudin C, Gonzalez-Martin J, de Jong BC, Rigouts L.

J Clin Microbiol. 2019 Aug 14. pii: JCM.00717-19. doi: 10.1128/JCM.00717-19. [Epub ahead of print]

4.

Fluoroquinolone heteroresistance in Mycobacterium tuberculosis: detection by genotypic and phenotypic assays in experimentally mixed populations.

Rigouts L, Miotto P, Schats M, Lempens P, Cabibbe AM, Galbiati S, Lampasona V, de Rijk P, Cirillo DM, de Jong BC.

Sci Rep. 2019 Aug 13;9(1):11760. doi: 10.1038/s41598-019-48289-9.

5.

Whole genome sequencing of Mycobacterium tuberculosis: current standards and open issues.

Meehan CJ, Goig GA, Kohl TA, Verboven L, Dippenaar A, Ezewudo M, Farhat MR, Guthrie JL, Laukens K, Miotto P, Ofori-Anyinam B, Dreyer V, Supply P, Suresh A, Utpatel C, van Soolingen D, Zhou Y, Ashton PM, Brites D, Cabibbe AM, de Jong BC, de Vos M, Menardo F, Gagneux S, Gao Q, Heupink TH, Liu Q, Loiseau C, Rigouts L, Rodwell TC, Tagliani E, Walker TM, Warren RM, Zhao Y, Zignol M, Schito M, Gardy J, Cirillo DM, Niemann S, Comas I, Van Rie A.

Nat Rev Microbiol. 2019 Sep;17(9):533-545. doi: 10.1038/s41579-019-0214-5. Review.

PMID:
31209399
6.

Multicentre study to establish interpretive criteria for clofazimine drug susceptibility testing.

Ismail NA, Said HM, Rodrigues C, Omar SV, Ajbani K, Sukhadiad N, Kohl TA, Niemann S, Kranzer K, Diels M, Rigouts L, Rüsch-Gerdes S, Siddiqi S.

Int J Tuberc Lung Dis. 2019 May 1;23(5):594-599. doi: 10.5588/ijtld.18.0417.

PMID:
31097068
7.

Storage of Sputum in Cetylpyridinium Chloride, OMNIgene.SPUTUM, and Ethanol Is Compatible with Molecular Tuberculosis Diagnostic Testing.

Sanoussi CN, de Jong BC, Affolabi D, Meehan CJ, Odoun M, Rigouts L.

J Clin Microbiol. 2019 Jun 25;57(7). pii: e00275-19. doi: 10.1128/JCM.00275-19. Print 2019 Jul.

8.

GWAS for quantitative resistance phenotypes in Mycobacterium tuberculosis reveals resistance genes and regulatory regions.

Farhat MR, Freschi L, Calderon R, Ioerger T, Snyder M, Meehan CJ, de Jong B, Rigouts L, Sloutsky A, Kaur D, Sunyaev S, van Soolingen D, Shendure J, Sacchettini J, Murray M.

Nat Commun. 2019 May 13;10(1):2128. doi: 10.1038/s41467-019-10110-6.

9.

Reference set of Mycobacterium tuberculosis clinical strains: A tool for research and product development.

Borrell S, Trauner A, Brites D, Rigouts L, Loiseau C, Coscolla M, Niemann S, De Jong B, Yeboah-Manu D, Kato-Maeda M, Feldmann J, Reinhard M, Beisel C, Gagneux S.

PLoS One. 2019 Mar 25;14(3):e0214088. doi: 10.1371/journal.pone.0214088. eCollection 2019.

10.

Xpert MTB/RIF assay for the diagnosis of extrapulmonary tuberculosis: a diagnostic evaluation study.

Tadesse M, Abebe G, Bekele A, Bezabih M, Yilma D, Apers L, de Jong BC, Rigouts L.

Clin Microbiol Infect. 2019 Aug;25(8):1000-1005. doi: 10.1016/j.cmi.2018.12.018. Epub 2018 Dec 22.

PMID:
30583052
11.

Mycobacterium africanum (Lineage 6) shows slower sputum smear conversion on tuberculosis treatment than Mycobacterium tuberculosis (Lineage 4) in Bamako, Mali.

Diarra B, Kone M, Togo ACG, Sarro YDS, Cisse AB, Somboro A, Degoga B, Tolofoudie M, Kone B, Sanogo M, Baya B, Kodio O, Maiga M, Belson M, Orsega S, Krit M, Dao S, Maiga II, Murphy RL, Rigouts L, Doumbia S, Diallo S, de Jong BC.

PLoS One. 2018 Dec 12;13(12):e0208603. doi: 10.1371/journal.pone.0208603. eCollection 2018.

12.

Low sensitivity of the MPT64 identification test to detect lineage 5 of the Mycobacterium tuberculosis complex.

Sanoussi CN, de Jong BC, Odoun M, Arekpa K, Ali Ligali M, Bodi O, Harris S, Ofori-Anyinam B, Yeboah-Manu D, Otchere ID, Asante-Poku A, Anagonou S, Gagneux S, Coscolla M, Rigouts L, Affolabi D.

J Med Microbiol. 2018 Dec;67(12):1718-1727. doi: 10.1099/jmm.0.000846. Epub 2018 Nov 2.

PMID:
30388066
13.

Integrating standardized whole genome sequence analysis with a global Mycobacterium tuberculosis antibiotic resistance knowledgebase.

Ezewudo M, Borens A, Chiner-Oms Á, Miotto P, Chindelevitch L, Starks AM, Hanna D, Liwski R, Zignol M, Gilpin C, Niemann S, Kohl TA, Warren RM, Crook D, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, McNerney R, Cirillo DM, Schito M, Rodwell TC, Posey J.

Sci Rep. 2018 Oct 18;8(1):15382. doi: 10.1038/s41598-018-33731-1.

14.

Whole genome sequence of Mycobacterium kansasii isolates of the genotype 1 from Brazilian patients with pulmonary disease demonstrates considerable heterogeneity.

Machado E, Vasconcellos SEG, Cerdeira C, Gomes LL, Junqueira R, Carvalho LD, Ramos JP, Redner P, Campos CED, Caldas PCS, Gomes APCS, Goldenberg T, Montes FF, Mello FCQ, Mussi VO, Lasunskaia E, Soolingen DV, Miranda AB, Rigouts L, Jong BC, Meehan CJ, Catanho M, Suffys PN.

Mem Inst Oswaldo Cruz. 2018 Jun 25;113(9):e180085. doi: 10.1590/0074-02760180085.

15.

Xpert Ultra Can Unambiguously Identify Specific Rifampin Resistance-Conferring Mutations.

Ng KCS, van Deun A, Meehan CJ, Torrea G, Driesen M, Gabriëls S, Rigouts L, André E, de Jong BC.

J Clin Microbiol. 2018 Aug 27;56(9). pii: e00686-18. doi: 10.1128/JCM.00686-18. Print 2018 Sep. No abstract available.

16.

Mycobacterial biomaterials and resources for researchers.

Hazbón MH, Rigouts L, Schito M, Ezewudo M, Kudo T, Itoh T, Ohkuma M, Kiss K, Wu L, Ma J, Hamada M, Strong M, Salfinger M, Daley CL, Nick JA, Lee JS, Rastogi N, Couvin D, Hurtado-Ortiz R, Bizet C, Suresh A, Rodwell T, Albertini A, Lacourciere KA, Deheer-Graham A, Alexander S, Russell JE, Bradford R, Riojas MA.

Pathog Dis. 2018 Jun 1;76(4). doi: 10.1093/femspd/fty042. Review.

17.

Performance of OMNIgene•SPUTUM (DNA Genotek) and cetylpyridinium chloride for sputum storage prior to mycobacterial culture.

Affolabi D, Sanoussi N, Sossou A, Nys T, Bodi O, Esse M, Houeto S, Massou F, de Jong BC, Rigouts L.

J Med Microbiol. 2018 May 2. doi: 10.1099/jmm.0.000745. [Epub ahead of print]

PMID:
29717969
18.

Genetic sequencing for surveillance of drug resistance in tuberculosis in highly endemic countries: a multi-country population-based surveillance study.

Zignol M, Cabibbe AM, Dean AS, Glaziou P, Alikhanova N, Ama C, Andres S, Barbova A, Borbe-Reyes A, Chin DP, Cirillo DM, Colvin C, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Hussain A, Ismail N, Kamal SMM, Khanzada FM, Kimerling M, Kohl TA, Mansjö M, Miotto P, Mukadi YD, Mvusi L, Niemann S, Omar SV, Rigouts L, Schito M, Sela I, Seyfaddinova M, Skenders G, Skrahina A, Tahseen S, Wells WA, Zhurilo A, Weyer K, Floyd K, Raviglione MC.

Lancet Infect Dis. 2018 Jun;18(6):675-683. doi: 10.1016/S1473-3099(18)30073-2. Epub 2018 Mar 21. Erratum in: Lancet Infect Dis. 2018 Mar 27;:.

19.

Potential Application of Digitally Linked Tuberculosis Diagnostics for Real-Time Surveillance of Drug-Resistant Tuberculosis Transmission: Validation and Analysis of Test Results.

Ng KC, Meehan CJ, Torrea G, Goeminne L, Diels M, Rigouts L, de Jong BC, André E.

JMIR Med Inform. 2018 Feb 27;6(1):e12. doi: 10.2196/medinform.9309.

20.

Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations.

Lempens P, Meehan CJ, Vandelannoote K, Fissette K, de Rijk P, Van Deun A, Rigouts L, de Jong BC.

Sci Rep. 2018 Feb 19;8(1):3246. doi: 10.1038/s41598-018-21378-x.

21.

The Repetitive Element RLEP Is a Highly Specific Target for Detection of Mycobacterium leprae.

Braet S, Vandelannoote K, Meehan CJ, Brum Fontes AN, Hasker E, Rosa PS, Lucena-Silva N, Rigouts L, Suffys PN, De Jong BC.

J Clin Microbiol. 2018 Feb 22;56(3). pii: e01924-17. doi: 10.1128/JCM.01924-17. Print 2018 Mar. No abstract available.

22.

A standardised method for interpreting the association between mutations and phenotypic drug resistance in Mycobacterium tuberculosis.

Miotto P, Tessema B, Tagliani E, Chindelevitch L, Starks AM, Emerson C, Hanna D, Kim PS, Liwski R, Zignol M, Gilpin C, Niemann S, Denkinger CM, Fleming J, Warren RM, Crook D, Posey J, Gagneux S, Hoffner S, Rodrigues C, Comas I, Engelthaler DM, Murray M, Alland D, Rigouts L, Lange C, Dheda K, Hasan R, Ranganathan UDK, McNerney R, Ezewudo M, Cirillo DM, Schito M, Köser CU, Rodwell TC.

Eur Respir J. 2017 Dec 28;50(6). pii: 1701354. doi: 10.1183/13993003.01354-2017. Print 2017 Dec.

23.

Half of rifampicin-resistant Mycobacterium tuberculosis complex isolated from tuberculosis patients in Sub-Saharan Africa have concomitant resistance to pyrazinamide.

Ngabonziza JCS, Diallo AB, Tagliani E, Diarra B, Kadanga AE, Togo ACG, Thiam A, de Rijk WB, Alagna R, Houeto S, Ba F, Dagnra AY, Ivan E, Affolabi D, Schwoebel V, Trebucq A, de Jong BC, Rigouts L, Daneau G; “Union short MDR-TB regimen study group”.

PLoS One. 2017 Oct 31;12(10):e0187211. doi: 10.1371/journal.pone.0187211. eCollection 2017.

24.

The predominance of Ethiopian specific Mycobacterium tuberculosis families and minimal contribution of Mycobacterium bovis in tuberculous lymphadenitis patients in Southwest Ethiopia.

Tadesse M, Abebe G, Bekele A, Bezabih M, de Rijk P, Meehan CJ, de Jong BC, Rigouts L.

Infect Genet Evol. 2017 Nov;55:251-259. doi: 10.1016/j.meegid.2017.09.016. Epub 2017 Sep 15.

PMID:
28919549
25.

Genotypic characterization directly applied to sputum improves the detection of Mycobacterium africanum West African 1, under-represented in positive cultures.

Sanoussi CN, Affolabi D, Rigouts L, Anagonou S, de Jong B.

PLoS Negl Trop Dis. 2017 Sep 1;11(9):e0005900. doi: 10.1371/journal.pntd.0005900. eCollection 2017 Sep.

26.

How should discordance between molecular and growth-based assays for rifampicin resistance be investigated?

Hofmann-Thiel S, Hoffmann H, Hillemann D, Rigouts L, Van Deun A, Kranzer K.

Int J Tuberc Lung Dis. 2017 Jul 1;21(7):721-726. doi: 10.5588/ijtld.17.0140.

PMID:
28633695
27.

Evaluation of a novel line probe assay to detect resistance to pyrazinamide, a key drug used for tuberculosis treatment.

Driesen M, Kondo Y, de Jong BC, Torrea G, Asnong S, Desmaretz C, Mostofa KSM, Tahseen S, Whitfield MG, Cirillo DM, Miotto P, Cabibbe AM, Rigouts L.

Clin Microbiol Infect. 2018 Jan;24(1):60-64. doi: 10.1016/j.cmi.2017.05.026. Epub 2017 Jun 3.

28.

Trend analysis suggested a change in subspecies among Mycobacterium avium isolated from pigs in Belgium, 1967-2013.

Soetaert K, Vluggen C, Duytschaever L, Denoël J, Roupie V, Smeets F, Bruffaerts N, Huygen K, Fretin D, Diels M, Rigouts L, Saegerman C, Mathys V.

Vet Rec. 2017 May 6;180(18):449. doi: 10.1136/vr.103951. Epub 2017 Mar 10. No abstract available.

29.

Virulence and immunogenicity of genetically defined human and porcine isolates of M. avium subsp. hominissuis in an experimental mouse infection.

Bruffaerts N, Vluggen C, Roupie V, Duytschaever L, Van den Poel C, Denoël J, Wattiez R, Letesson JJ, Fretin D, Rigouts L, Chapeira O, Mathys V, Saegerman C, Huygen K.

PLoS One. 2017 Feb 9;12(2):e0171895. doi: 10.1371/journal.pone.0171895. eCollection 2017.

30.

The majority of patients with multidrug-resistant tuberculosis in Sub-Saharan Africa present a concomitant resistance to pyrazinamide.

Daneau G, Gumusboga M, De Rijk P, Trebucq A, Rigouts L, Van Deun A, de Jong BC.

Int J Mycobacteriol. 2016 Dec;5 Suppl 1:S46-S47. doi: 10.1016/j.ijmyco.2016.10.015. Epub 2016 Oct 27.

31.

Unexpected high prevalence of resistance-associated Rv0678 variants in MDR-TB patients without documented prior use of clofazimine or bedaquiline.

Villellas C, Coeck N, Meehan CJ, Lounis N, de Jong B, Rigouts L, Andries K.

J Antimicrob Chemother. 2017 Mar 1;72(3):684-690. doi: 10.1093/jac/dkw502.

32.
33.

Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project.

Zignol M, Dean AS, Alikhanova N, Andres S, Cabibbe AM, Cirillo DM, Dadu A, Dreyer A, Driesen M, Gilpin C, Hasan R, Hasan Z, Hoffner S, Husain A, Hussain A, Ismail N, Kamal M, Mansjö M, Mvusi L, Niemann S, Omar SV, Qadeer E, Rigouts L, Ruesch-Gerdes S, Schito M, Seyfaddinova M, Skrahina A, Tahseen S, Wells WA, Mukadi YD, Kimerling M, Floyd K, Weyer K, Raviglione MC.

Lancet Infect Dis. 2016 Oct;16(10):1185-1192. doi: 10.1016/S1473-3099(16)30190-6. Epub 2016 Jul 7.

34.

Increased detection of smear-negative pulmonary tuberculosis by GeneXpert MTB/RIF® assay after bleach concentration.

Tadesse M, Aragaw D, Rigouts L, Abebe G.

Int J Mycobacteriol. 2016 Jun;5(2):211-8. doi: 10.1016/j.ijmyco.2016.03.005. Epub 2016 Apr 19.

35.

Use of RODAC plates to measure containment of Mycobacterium tuberculosis in a Class IIB biosafety cabinet during routine operations.

Daneau G, Nduwamahoro E, Fissette K, Rüdelsheim P, van Soolingen D, de Jong BC, Rigouts L.

Int J Mycobacteriol. 2016 Jun;5(2):148-54. doi: 10.1016/j.ijmyco.2016.01.003. Epub 2016 Feb 17.

36.

Geographic Differences in the Contribution of ubiA Mutations to High-Level Ethambutol Resistance in Mycobacterium tuberculosis.

Lingaraju S, Rigouts L, Gupta A, Lee J, Umubyeyi AN, Davidow AL, German S, Cho E, Lee JI, Cho SN, Kim CT, Alland D, Safi H.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):4101-5. doi: 10.1128/AAC.03002-15. Print 2016 Jul.

37.

Diverse Molecular Genotypes of Mycobacterium tuberculosis Complex Isolates Circulating in the Free State, South Africa.

Van der Spoel van Dijk A, Makhoahle PM, Rigouts L, Baba K.

Int J Microbiol. 2016;2016:6572165. doi: 10.1155/2016/6572165. Epub 2016 Mar 17.

38.

Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance.

Phelan J, Coll F, McNerney R, Ascher DB, Pires DE, Furnham N, Coeck N, Hill-Cawthorne GA, Nair MB, Mallard K, Ramsay A, Campino S, Hibberd ML, Pain A, Rigouts L, Clark TG.

BMC Med. 2016 Mar 23;14:31. doi: 10.1186/s12916-016-0575-9.

39.

Genetic Determinants of Drug Resistance in Mycobacterium tuberculosis and Their Diagnostic Value.

Farhat MR, Sultana R, Iartchouk O, Bozeman S, Galagan J, Sisk P, Stolte C, Nebenzahl-Guimaraes H, Jacobson K, Sloutsky A, Kaur D, Posey J, Kreiswirth BN, Kurepina N, Rigouts L, Streicher EM, Victor TC, Warren RM, van Soolingen D, Murray M.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):621-30. doi: 10.1164/rccm.201510-2091OC.

40.

Correlation of different phenotypic drug susceptibility testing methods for four fluoroquinolones in Mycobacterium tuberculosis.

Coeck N, de Jong BC, Diels M, de Rijk P, Ardizzoni E, Van Deun A, Rigouts L.

J Antimicrob Chemother. 2016 May;71(5):1233-40. doi: 10.1093/jac/dkv499. Epub 2016 Feb 6.

41.

Genotyping and strain distribution of Mycobacterium avium subspecies hominissuis isolated from humans and pigs in Belgium, 2011-2013.

Vluggen C, Soetaert K, Duytschaever L, Denoël J, Fauville-Dufaux M, Smeets F, Bruffaerts N, Huygen K, Fretin D, Rigouts L, Saegerman C, Mathys V.

Euro Surveill. 2016;21(3):30111. doi: 10.2807/1560-7917.ES.2016.21.3.30111.

42.

The thin-layer agar method for direct phenotypic detection of multi- and extensively drug-resistant tuberculosis.

Ardizzoni E, Mulders W, Kotrikadze T, Aspindzelashvili R, Goginashvili L, Pangtey H, Varaine F, Bastard M, Rigouts L, de Jong BC.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1547-52. doi: 10.5588/ijtld.15.0136.

PMID:
26614200
43.

Systematic screening for drug-resistant tuberculosis with Xpert(®) MTB/RIF in a referral hospital in Cambodia.

Lorent N, Kong C, Kim T, Sam S, Thai S, Colebunders R, Rigouts L, Lynen L.

Int J Tuberc Lung Dis. 2015 Dec;19(12):1528-35. doi: 10.5588/ijtld.14.0956.

PMID:
26614197
44.

Specific gyrA gene mutations predict poor treatment outcome in MDR-TB.

Rigouts L, Coeck N, Gumusboga M, de Rijk WB, Aung KJ, Hossain MA, Fissette K, Rieder HL, Meehan CJ, de Jong BC, Van Deun A.

J Antimicrob Chemother. 2016 Feb;71(2):314-23. doi: 10.1093/jac/dkv360. Epub 2015 Nov 24.

45.

GeneXpert MTB/RIF Assay for the Diagnosis of Tuberculous Lymphadenitis on Concentrated Fine Needle Aspirates in High Tuberculosis Burden Settings.

Tadesse M, Abebe G, Abdissa K, Aragaw D, Abdella K, Bekele A, Bezabih M, Apers L, de Jong BC, Rigouts L.

PLoS One. 2015 Sep 14;10(9):e0137471. doi: 10.1371/journal.pone.0137471. eCollection 2015.

46.

First insights into circulating Mycobacterium tuberculosis complex lineages and drug resistance in Guinea.

Ejo M, Gehre F, Barry MD, Sow O, Bah NM, Camara M, Bah B, Uwizeye C, Nduwamahoro E, Fissette K, De Rijk P, Merle C, Olliaro P, Burgos M, Lienhardt C, Rigouts L, de Jong BC.

Infect Genet Evol. 2015 Jul;33:314-9. doi: 10.1016/j.meegid.2015.05.022. Epub 2015 May 21.

47.

Bedaquiline susceptibility testing of Mycobacterium tuberculosis in an automated liquid culture system.

Torrea G, Coeck N, Desmaretz C, Van De Parre T, Van Poucke T, Lounis N, de Jong BC, Rigouts L.

J Antimicrob Chemother. 2015 Aug;70(8):2300-5. doi: 10.1093/jac/dkv117. Epub 2015 May 14.

PMID:
25977401
48.

Predominant Mycobacterium tuberculosis Families and High Rates of Recent Transmission among New Cases Are Not Associated with Primary Multidrug Resistance in Lima, Peru.

Barletta F, Otero L, de Jong BC, Iwamoto T, Arikawa K, Van der Stuyft P, Niemann S, Merker M, Uwizeye C, Seas C, Rigouts L.

J Clin Microbiol. 2015 Jun;53(6):1854-63. doi: 10.1128/JCM.03585-14. Epub 2015 Mar 25.

49.

[Resistance to second-line anti-tuberculosis drugs among peruvian multidrug resistant Mycobacterium tuberculosis strains].

Barletta F, Zamudio C, Rigouts L, Seas C.

Rev Peru Med Exp Salud Publica. 2014 Oct-Dec;31(4):676-82. Spanish.

50.

Disputed rpoB mutations can frequently cause important rifampicin resistance among new tuberculosis patients.

Van Deun A, Aung KJ, Hossain A, de Rijk P, Gumusboga M, Rigouts L, de Jong BC.

Int J Tuberc Lung Dis. 2015 Feb;19(2):185-90. doi: 10.5588/ijtld.14.0651.

PMID:
25574917

Supplemental Content

Loading ...
Support Center